378 related articles for article (PubMed ID: 25381039)
1. Some economics on personalized and predictive medicine.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Eur J Health Econ; 2015 Dec; 16(9):985-94. PubMed ID: 25381039
[TBL] [Abstract][Full Text] [Related]
2. Current methodological issues in the economic assessment of personalized medicine.
Annemans L; Redekop K; Payne K
Value Health; 2013; 16(6 Suppl):S20-6. PubMed ID: 24034308
[TBL] [Abstract][Full Text] [Related]
3. The economic value of personalized medicine tests: what we know and what we need to know.
Phillips KA; Ann Sakowski J; Trosman J; Douglas MP; Liang SY; Neumann P
Genet Med; 2014 Mar; 16(3):251-7. PubMed ID: 24232413
[TBL] [Abstract][Full Text] [Related]
4. Implementation of personalized medicine in a context of moral hazard and uncertainty about treatment efficacy.
Alcenat S; Maréchal F; Naegelen F
Int J Health Econ Manag; 2021 Mar; 21(1):81-97. PubMed ID: 33201335
[TBL] [Abstract][Full Text] [Related]
5. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?
Husereau D; Marshall DA; Levy AR; Peacock S; Hoch JS
Int J Technol Assess Health Care; 2014 Apr; 30(2):179-87. PubMed ID: 24806420
[TBL] [Abstract][Full Text] [Related]
6. ["Screening" in special situations. Assessing predictive genetic screening for hereditary breast and colorectal cancer].
Jonas S; Wild C; Schamberger C
Z Arztl Fortbild Qualitatssich; 2003 Feb; 97(1):67-71. PubMed ID: 12669692
[TBL] [Abstract][Full Text] [Related]
7. Essential elements of personalized medicine.
Burke W; Brown Trinidad S; Press NA
Urol Oncol; 2014 Feb; 32(2):193-7. PubMed ID: 24321254
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and health economic challenges of personalized medicine].
Brüggenjürgen B; Kornbluth L; Ferrara JV; Willich SN
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):710-4. PubMed ID: 22526860
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of prenatal population screening for fragile X syndrome.
Hollingsworth B; Harris A
Community Genet; 2005; 8(2):68-72. PubMed ID: 15925881
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.
Roth JA; Ramsey SD; Carlson JJ
Oncologist; 2015 Dec; 20(12):1355-64. PubMed ID: 26482553
[TBL] [Abstract][Full Text] [Related]
11. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
[TBL] [Abstract][Full Text] [Related]
13. [Personalized medicine--the future is already here].
Abadi-Korek I; Shemer J
Harefuah; 2011 May; 150(5):451-2, 490. PubMed ID: 21678641
[TBL] [Abstract][Full Text] [Related]
14. Value of information on preference heterogeneity and individualized care.
Basu A; Meltzer D
Med Decis Making; 2007; 27(2):112-27. PubMed ID: 17409362
[TBL] [Abstract][Full Text] [Related]
15. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
16. Pre-approval incentives to promote adoption of personalized medicine: a theoretical approach.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Health Econ Rev; 2019 Oct; 9(1):28. PubMed ID: 31664604
[TBL] [Abstract][Full Text] [Related]
17. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble B
Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
[TBL] [Abstract][Full Text] [Related]
18. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
Frueh FW
Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
[TBL] [Abstract][Full Text] [Related]
19. The importance of test accuracy in economic evaluations of companion diagnostics.
San Miguel L; Hulstaert F
J Comp Eff Res; 2015 Nov; 4(6):569-77. PubMed ID: 26529499
[TBL] [Abstract][Full Text] [Related]
20. Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
Hoogendoorn M; Feenstra TL; Asukai Y; Briggs AH; Borg S; Dal Negro RW; Hansen RN; Jansson SA; Leidl R; Risebrough N; Samyshkin Y; Wacker ME; Rutten-van Mölken MPMH
Value Health; 2016; 19(6):800-810. PubMed ID: 27712708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
